Ignite Creation Date:
2024-05-05 @ 10:13 PM
Last Modification Date:
2024-10-26 @ 10:15 AM
Study NCT ID:
NCT01058356
Status:
COMPLETED
Last Update Posted:
2010-04-20
First Post:
2010-01-26
Brief Title:
Effect of Probiotic Lactobacilli Lacidofil Cap for the Prevention of Antibiotic-Associated Diarrhea
Sponsor:
Pharmbio Korea Co Ltd
Organization:
Pharmbio Korea Co Ltd
Study Overview
Official Title:
Effect of Probiotic Lactobacilli Lacidofil Cap for the Prevention of Antibiotic-Associated Diarrhea Prospective Randomized Double-blind Multicenter Study
Status:
COMPLETED
Status Verified Date:
2010-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Antibiotic-Associated Diarrhea AAD is a common complication of antibiotic use The frequency of AAD can be high 26 - 60 or moderate 13-29 during hospital outbreaks and is relatively infrequent in outpatients The risk factors for AAD include broad-spectrum antibiotics host factors age health status and gender hospitalization period and exposure to nosocomial pathogens AAD occurs 2-8 weeks after exposure to antibiotics as a result of disrupting normal intestinal microflora One of the roles of normal intestinal microflora is to act as a protective barrier that resists the colonization of intestinal pathogens These patients are susceptible to infection by opportunistic pathogens without this protective barrier Probiotic therapy is suited to AAD and Clostridium difficile disease Probiotics assist in reestablishing the disrupted intestinal microflora enhancing immune responses and clearing pathogens and their toxins from the host Studies using probiotics have been reported for the past twenty-eight years 19772005 but the studies have been variable in trial designs and types of probiotics had differing doses and durations of treatment and thus have yielded controversial results The investigators will conduct a multi-center randomized placebo-controlled double-blind trial to assess the efficacy of the probiotic Lactobacilli Lacidofil cap for the prevention of AAD in adults
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None